Prostate cancer incidence statistics

Cases

New cases of prostate cancer, 2016-2018, UK

 

Proportion of all cases

Percentage prostate cancer is of total cancer cases, 2016-2018 average, UK

 

Age

Peak rate of prostate cancer cases, 2016-2018, UK

 

Trend over time

Change in prostate cancer incidence rates since the early 1990s, Males, UK

 

Prostate cancer is the most common cancer in males in the UK, accounting for 27% of all new cancer cases in males (2016-2018).In females and males combined, prostate cancer is the 2nd most common cancer in the UK, accounting for 14% of all new cancer cases (2016-2018).[1-4]

Prostate cancer incidence rates (European age-standardised (AS) rate Open a glossary item) for males are significantly higher than the UK average in England and Wales and significantly lower than the UK average in Scotland and Northern Ireland.

For prostate cancer, there are few established risk factors therefore differences between countries largely reflect differences in diagnosis and data recording.

Prostate Cancer (C61), Average Number of New Cases Per Year, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2016-2018

  England Scotland Wales Northern Ireland UK
Male Cases 44,365 3,761 2,919 1,209 52,254
Crude Rate 161.4 142.5 189.5 131.3 160.4
AS Rate 186.4 157.3 193.2 166.3 183.8
AS Rate - 95% LCL 185.4 154.4 189.1 160.9 182.9
AS Rate - 95% UCL 187.4 160.2 197.2 171.7 184.7
Persons Cases 44,365 3,761 2,919 1,209 52,254
Crude Rate 79.8 69.4 93.4 64.6 79.1
AS Rate 86.5 71.3 89.8 75.7 85.1
AS Rate - 95% LCL 86.0 70.0 88.0 73.2 84.7
AS Rate - 95% UCL 87.0 72.6 91.7 78.2 85.5

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item
 

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, July 2021. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2020. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were published by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2018/, March 2021.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2020. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2016-2018, ICD-10 C61.

Last reviewed:

Prostate cancer incidence is strongly related to age, with the highest incidence rates being in older men. In the UK in 2016-2018, on average each year around a third of new cases (34%) were in males aged 75 and over.[1-4]

Age-specific incidence rates rise steeply from around age 45-49, peak in the 75-79 age group before dropping slightly and remaining stable in the oldest age groups.The highest rates are in in the 75 to 79 age group.

Prostate cancer (C61), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Male Population, UK, 2016-2018

For prostate cancer, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

The age distribution of prostate cancer cases probably partly reflects the age groups in which prostate specific antigen (PSA) testing and transurethral resection of the prostate (TURP) are carried out.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, July 2021. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2020. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were published by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2018/, March 2021.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2020. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2016-2018, ICD-10 C61.

Last reviewed:

Prostate cancer European age-standardised (AS) Open a glossary item incidence rates for males increased by 48% in the UK between 1993-1995 and 2016-2018.[1-4]

Over the last decade in the UK (between 2006-2008 and 2016-2018), prostate cancer AS incidence rates for males increased by 8%.

Prostate Cancer (C61), European Age-Standardised Incidence Rates, Males, UK, 1993 to 2018

Prostate cancer incidence rates have increased overall in some broad age groups in males in the UK since the early 1990s, but have decreased or remained stable in others.[1-4] Rates in 0-24s have remained stable, in 25-49s have increased by 584%, in 50-59s have increased by 327%, in 60-69s have increased by 152%, in 70-79s have increased by 49% and in 80+s have decreased by 27%.

Prostate Cancer (C61), European Age-Standardised Incidence Rates per 100,000 Male Population, By Age, UK, 1993-2018

Prostate cancer incidence trends clearly reflect incidental detection of asymptomatic disease through transurethral resection of the prostate (TURP) and prostate specific antigen (PSA) testing. PSA testing was introduced in the late 1980s and an estimated 10-20% of men in Europe have had the test.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, July 2021. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2020. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were published by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/cancer-incidence-in-wales-2002-2018/, March 2021.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2020. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1993-2018, ICD-10 C61.

Last reviewed:

Prostate cancer incidence rates are projected to rise by 12% in the UK between 2014 and 2035, to 233 cases per 100,000 males by 2035.[1]

Prostate cancer (C61), Observed and Projected Age-Standardised Incidence Rates, by Sex, UK, 1979-2035

It is projected that 77,349 cases of prostate cancer will be diagnosed in the UK in 2035.

References

  1. Smittenaar CR, Petersen KA, Stewart K, Moitt N. Cancer Incidence and Mortality Projections in the UK Until 2035. Brit J Cancer 2016.

About this data

Data is for: UK, 1979-2014 (observed), 2015-2035 (projected), ICD-10 C61

Projections are based on observed incidence and mortality rates and therefore implicitly include changes in cancer risk factors, diagnosis and treatment. It is not possible to assess the statistical significance of changes between 2014 (observed) and 2035 (projected) figures. Confidence intervals are not calculated for the projected figures. Projections are by their nature uncertain because unexpected events in future could change the trend. It is not sensible to calculate a boundary of uncertainty around these already uncertain point estimates. Changes are described as 'increase' or 'decrease' if there is any difference between the point estimates.

More on projections methodology

Last reviewed:

Prostate cancer incidence rates (European age-standardised (AS) rates Open a glossary item) in England in males are 17% lower in the most deprived quintile compared with the least (2013-2017).[1]

It is estimated that there are around 3,100 fewer cases of prostate cancer each year in England than there would be if every deprivation quintile had the same age-specific crude incidence rates as the least deprived quintile.

Prostate Cancer (C61), Estimated Average Number of Fewer Cases per Year, by Deprivation Quintile, England, 2013-2017

Prostate Cancer (C61), European Age-Standardised Incidence Rates per 100,000 Population, by Deprivation Quintile, England, 2013-2017

References

  1. Calculated by the Cancer Intelligence Team at Cancer Research UK, April 2020. Based on method reported in National Cancer Intelligence Network Cancer by Deprivation in England Incidence, 1996-2010 Mortality, 1997-2011 . Using cancer incidence data 2013-2017 (Public Health England) and population data 2013-2017 (Office for National Statistics) by Indices of Multiple Deprivation 2015 income domain quintile, cancer type, sex, and five-year age band.

About this data

Data is for England, 2013-2017, ICD-10 C61.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.